PN

The Pennant Group, Inc.

PNTGHealthcareNASDAQ

Medical Care Facilities

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$947.7M
+36.3% YoY
Net Income
$29.6M
+31.1% YoY
EBITDA
$60.8M
+36.9% YoY
Free Cash Flow
$2.7M

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 31CONFIRMED RSI OversoldRSI 26.2, below 30, stock may be oversold
Aug 29CONFIRMED RSI OversoldRSI 26.2, below 30, stock may be oversold
About The Pennant Group, Inc.

The Pennant Group, Inc. provides healthcare services in the United States. At a $1.33B market cap, The Pennant Group, Inc. ranks as a small-cap company within healthcare. It operates in two segments, Home Health and Hospice Services, and Senior Living Services.

Where PNTG stands vs its 150-day and 200-day moving averages

As of the August 31, 2026 close, PNTG finished 8.23% above its 150-day moving average ($34.26) and 13.05% above its 200-day moving average ($32.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is PNTG overbought or oversold?

At the August 31, 2026 close, PNTG's RSI(14) was 26.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.33B
P/E (TTM)42.22
Fwd P/E23.94
EPS$0.90
Beta1.27
52W Change+57.2%
ROE10.4%
Analysis

The Pennant Group, Inc. carries $495.6M in total debt against $15.3M in cash reserves — debt is roughly 32.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $2.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 10.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $439.7M (2021) to $947.7M (2025), reflecting a 116% increase over the period.

The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing PNTG's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms